Check this out:
http://www.medscape.com/viewarticle/579457
you may have to join to read it...but that is free and easy.
Quote:
August 22, 2008 — Strontium ranelate is effective in younger postmenopausal women aged 50 to 65 years with severe osteoporosis, according to the results of a study reported in the August 19 Online First issue of the Annals of the Rheumatic Diseases.
"Early osteoporotic fractures have a great impact on the disease progression, the first fracture being a major risk factor for further fractures," write Christian Roux, from Université Paris-Descartes in Paris, France, and colleagues. "Subsequently, the efficacy of antiosteoporotic treatments in the younger women appears of utmost interest. Strontium ranelate is an antiosteoporotic treatment, simultaneously reducing bone resorption while promoting bone formation."
In the Spinal Osteoporosis Therapeutic Intervention, an international, double-blind, placebo-controlled trial, strontium ranelate 2 g/day orally was effective in reducing the risk for vertebral fractures in postmenopausal women with osteoporosis and a prevalent vertebral fracture. The present analysis included data collected during 4 years in 353 women aged 50 to 65 years who were enrolled and randomly assigned in the Spinal Osteoporosis Therapeutic Intervention.
|
more on strontium:
http://www.algaecal.com/strontium.html
D2 is the storage form of Vit D.
D3 is the active form.
This PubMed article compares treatments:
Quote:
Rev Med Brux. 2008 Sep;29(4):301-9.Links
[Update on treatment of postmenopausal osteoporosis]
[Article in French]
Body JJ.
Service de Médecine, C.H.U. Brugmann, Bruxelles. jean-jacques.body@chu-brugmann.be
The most frequent sites of osteoporotic fractures are the vertebrae, the hip, the forearm and the proximal humerus. Drugs that inhibit bone resorption constitute the mainstay for the treatment of postmenopausal osteoporosis. A recent meta-analysis indicates that vitamin D can reduce the risk of hip fractures only if calcium supplements are also administered. The effect of hormone replacement therapy on the risk of non vertebral fractures is less clear than on vertebral fractures. Raloxifene (a SERM) reduces the rate of vertebral fractures and of breast cancer, but it does not protect against hip fracture. Bisphosphonates are the most commonly used compounds to treat postmenopausal osteoporosis. The level of evidence for currently used bisphosphonates (alendronate, ibandronate, risedronate, zoledronate) to reduce vertebral fracture rate is maximal. Results of controlled clinical trials indicate a reduction in the risk of vertebral fractures of 40-50% and of 20-40% for non vertebral fractures, including hip fractures. However, their relative efficacy on hip fractures has been less well studied and remains more controversial. Long-term compliance of bisphosphonate therapy is improved by intermittent schemes. The most recent developpements concern the intravenous administration of ibandronate and even more of zoledronate (yearly infusions). The reduction in the rate of vertebral and hip fractures has been demonstrated in the main zoledronate trial and a prolongation of survival has been shown in the study including patients with a recent hip fracture. Whereas hyperparathyroidism is a cause of bone loss, the intermittent administration of parathyroid hormone or of its 1-34 fragment (teriparatide) exerts anabolic effects on the skeleton. The treatment is demanding and costly (daily sc injections during 18 months), requires some monitoring (serum and urinary calcium) but the results, at least for vertebral fractures, are quite favorable. Strontium ranelate is a less powerful stimulator of bone formation but it also reduces bone resorption. Its daily administration for 3 years reduces the risk of vertebral fractures and, to a lesser extent, of non vertebral fractures. Lastly, denosumab is a high affinity antibody against RANK Ligand that specifically blocks the formation and the activity of osteoclasts. The efficacy of this promising compound will soon be known.
PMID: 18949981 [PubMed - indexed for MEDLINE]
|
I can understand your concerns. If it were me?
I'd get that Vit D up and try the strontium containing supplements. They are becoming more common now.
Low Vit D levels cause a secondary hyperparathyroidism.
read more here:
http://www.parathyroid.com/low-vitamin-d.htm
__________________
All truths are easy to understand once they are discovered; the point is to discover them.-- Galileo Galilei
************************************
.
Weezie looking at petunias 8.25.2017
****************************
These forums are for mutual support and information sharing only. The forums are not a substitute for medical advice, diagnosis or treatment provided by a qualified health care provider. Always consult your doctor before trying anything you read here.